Field Trip Discovery and Field Trip Health have been reorganized into two separate companies. The Discovery division has been renamed Reunion Neuroscience Inc. and may be found on NASDAQ and CSE as “REUN”, while Field Trip Health is now Field Trip Health & Wellness Ltd. (Field Trip H&W) and is listed at the CSE as “FTHW”.
Reunion Neuroscience continues advancing its drug R&D pipeline. The company’s lead asset, RE-104 (formerly FT-104), is a potential fast-acting antidepressant with durable efficacy and therefore plausible for post-partum and treatment-resistant depression therapies, while the FT-200 series includes compounds with potentially reduced psychoactivity and therefore propitious for chronic treatments.
